| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0149-2918(04)90066-5 |
| P698 | PubMed publication ID | 15220010 |
| P50 | author | M. Lynn Crismon | Q111749060 |
| P2093 | author name string | Nick C Patel | |
| Anthony DeLeon | |||
| P2860 | cites work | Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. | Q43844457 |
| Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. | Q43847484 | ||
| Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors | Q44028935 | ||
| Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol | Q44055480 | ||
| Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. | Q44167467 | ||
| Aripiprazole: does partial dopaminergic agonism translate into clinical benefits? | Q44412619 | ||
| Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials | Q44428863 | ||
| Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder | Q44513113 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia | Q44649979 | ||
| Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. | Q44662788 | ||
| Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra | Q48088371 | ||
| Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors | Q48392880 | ||
| Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area | Q48940484 | ||
| Radioreceptor binding profile of the atypical antipsychotic olanzapine | Q49130929 | ||
| Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain | Q70812948 | ||
| Schizophrenia | Q79226206 | ||
| Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects | Q28327576 | ||
| Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes | Q28375923 | ||
| A double-blind pilot study of risperidone in the treatment of conduct disorder | Q28376547 | ||
| Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis | Q32068772 | ||
| Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study | Q33186211 | ||
| The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor | Q33959664 | ||
| Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride | Q33959951 | ||
| Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia | Q34507860 | ||
| Partial dopamine agonists in the treatment of psychosis | Q34603506 | ||
| The neurobiology and control of anxious states | Q35202929 | ||
| Mechanism of new antipsychotic medications: occupancy is not just antagonism | Q35558773 | ||
| Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum | Q38348350 | ||
| Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence | Q41682564 | ||
| "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics. | Q43780540 | ||
| P433 | issue | 5 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 649-666 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Clinical Therapeutics | Q15716601 |
| P1476 | title | Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability | |
| P478 | volume | 26 |
| Q37067125 | 2-Bromoterguride-a potential atypical antipsychotic drug without metabolic effects in rats. |
| Q37326130 | A UK consensus on the administration of aripiprazole for the treatment of mania |
| Q46886125 | A case of Aripiprazole and extra pyramidal side effects |
| Q79212271 | A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole |
| Q36853249 | A case series: evaluation of the metabolic safety of aripiprazole |
| Q46170156 | A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder |
| Q37510958 | A review of the safety and tolerability of aripiprazole |
| Q38111956 | A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder |
| Q35188726 | Active-state model of a dopamine D2 receptor-Gαi complex stabilized by aripiprazole-type partial agonists |
| Q48512330 | Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia |
| Q45229981 | Adjunctive aripiprazole for bupropion-resistant major depression |
| Q46055786 | Adjunctive aripiprazole in bipolar I depression |
| Q34925151 | Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials |
| Q49472268 | Adsorptive stripping voltammetric methods for determination of aripiprazole |
| Q24649568 | Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia |
| Q37959135 | An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients |
| Q34642676 | An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression |
| Q36062184 | An update of safety of clinically used atypical antipsychotics |
| Q38830416 | Antipsychotic drugs in Huntington's disease. |
| Q33755676 | Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole |
| Q42975239 | Aripiprazole - a medical treatment alternative for Tourette Syndrome in childhood and adolescence |
| Q33650040 | Aripiprazole Facilitates Extinction of Conditioned Fear in Adolescent Rats. |
| Q47895142 | Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self-Control. |
| Q46446352 | Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors |
| Q36846918 | Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats |
| Q33799660 | Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data |
| Q44735526 | Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. |
| Q46128379 | Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects |
| Q34013720 | Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control |
| Q35015469 | Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence |
| Q36405102 | Aripiprazole for the treatment of Tourette's disorder |
| Q37831357 | Aripiprazole for the treatment of bipolar disorder: a review of current evidence |
| Q37835845 | Aripiprazole for the treatment of irritability associated with autism |
| Q64114058 | Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series |
| Q46208591 | Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports |
| Q34605438 | Aripiprazole in schizotypal personality disorder: a case report |
| Q37133284 | Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence |
| Q41982065 | Aripiprazole therapy for nicotine dependence |
| Q37947687 | Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment |
| Q43024905 | Aripiprazole worsens psychosis: a case report |
| Q39244947 | Aripiprazole, a Drug that Displays Partial Agonism and Functional Selectivity |
| Q36808054 | Aripiprazole: pharmacology and evidence in bipolar disorder |
| Q34558285 | Aripiprazole: pharmacology, efficacy, safety and tolerability |
| Q36584260 | Atypical antipsychotics in the treatment of depressive and psychotic symptoms in patients with chronic schizophrenia: a naturalistic study |
| Q27311205 | Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC. |
| Q37111054 | Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats |
| Q89145780 | Clinical Pharmacokinetics of Atypical Antipsychotics: An Update |
| Q36804367 | Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response |
| Q35728228 | Clinical pharmacology of atypical antipsychotics: an update. |
| Q34529810 | Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania |
| Q33925658 | Delirium in advanced age and dementia: A prolonged refractory course of delirium and lower functional status. |
| Q41433244 | Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands |
| Q37025888 | Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits |
| Q99566745 | Differential effects of different antipsychotic drugs on cognitive function in patients with chronic schizophrenia |
| Q34660695 | Dissociable control of impulsivity in rats by dopamine d2/3 receptors in the core and shell subregions of the nucleus accumbens |
| Q37714573 | Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice |
| Q38207705 | Drugs currently in Phase II clinical trials for cocaine addiction |
| Q55431729 | Early antipsychotic treatment in juvenile rats elicits long-term alterations to the adult serotonin receptors. |
| Q40921574 | Effect of combination of aripiprazole with carbamazepine and fluvoxamine on liver functions in experimental animals |
| Q57526943 | Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder |
| Q51526215 | Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol. |
| Q47207523 | Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). |
| Q34009852 | Effects of aripiprazole on subjective and physiological responses to alcohol |
| Q46927168 | Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex |
| Q37299210 | Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review |
| Q33695789 | Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review |
| Q33518314 | Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials |
| Q36588607 | Evidence review and clinical guidance for the use of ziprasidone in Canada |
| Q36133796 | First-episode schizophrenia: a focus on pharmacological treatment and safety considerations |
| Q64039164 | From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone |
| Q28306632 | Gilles de la Tourette syndrome: the complexities of phenotype and treatment |
| Q30849611 | Hippocampal and thalamic neuronal metabolism in a putative rat model of schizophrenia |
| Q37948917 | Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature |
| Q39555488 | Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions |
| Q48292762 | In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain |
| Q34527796 | Incontinence and mood disorder: is there an association? |
| Q42290095 | Low-Dose Aripiprazole Augmentation in Amitriptyline-Resistant Burning Mouth Syndrome: Results from Two Cases. |
| Q38689883 | Lurasidone for the treatment of irritability and anger in autism spectrum disorders |
| Q37316813 | Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole |
| Q41828115 | Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole |
| Q34772251 | New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling |
| Q34613057 | Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders |
| Q50205908 | Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre |
| Q41901628 | Palau'chlor: a practical and reactive chlorinating reagent |
| Q48607362 | Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities |
| Q54119984 | Potentiating and synergistic effect of grapefruit juice on the antioxidant and anti-inflammatory activity of aripiprazole against hydrogen peroxide induced oxidative stress in mice. |
| Q40200910 | Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics |
| Q36216477 | Pretreatment or Posttreatment with Aripiprazole Attenuates Methamphetamine-induced Stereotyped Behavior in Mice |
| Q35062881 | Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse |
| Q28273912 | Role of Dopamine 2 Receptor in Impaired Drug-Cue Extinction in Adolescent Rats |
| Q34154951 | Schizophrenia: overview and treatment options |
| Q38125219 | Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. |
| Q48943125 | Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood |
| Q45020983 | Sudden unexpected death in epilepsy associated with progressive deterioration in heart rate variability |
| Q64330025 | TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel |
| Q47624983 | The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders. |
| Q36094872 | The art of prescribing. Principles of switching novel antipsychotic medications |
| Q36677469 | The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics |
| Q42464924 | The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia |
| Q33619940 | The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. |
| Q42599261 | The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. |
| Q58861808 | Thermal stability of aripiprazole monohydrate investigated by Raman spectroscopy |
| Q46057245 | Transition-Metal-Free Decarboxylative Iodination: New Routes for Decarboxylative Oxidative Cross-Couplings. |
| Q41528294 | Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole |
| Q38334922 | Treatment of clozapine-associated weight gain: a systematic review. |
| Q42101428 | Unexpected effect of aripiprazole on nociceptive pain |
| Q28546441 | Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats |
| Q42852114 | Validated spectrophotometric quantification of aripiprazole in pharmaceutical formulations by using multivariate technique |
| Q26899110 | XMetDB: an open access database for xenobiotic metabolism |
Search more.